|
|
|
|
| LEADER |
02312nam a2200313 u 4500 |
| 001 |
EB002202522 |
| 003 |
EBX01000000000000001339725 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240412 r ||| eng |
| 100 |
1 |
|
|a Kerr, Christine
|
| 245 |
0 |
0 |
|a Pretreatment assessment in adults with chronic hepatitis C virus infection
|h Elektronische Ressource
|c lead author, Christine A. Kerr ; writing group, Joshua S. Aron, David E. Bernstein, Colleen Flanigan, Christopher J. Hoffmann, Charles J. Gonzalez
|
| 246 |
3 |
1 |
|a Pretreatment assessment in adults with chronic HCV infection
|
| 260 |
|
|
|a [Baltimore]
|b [Johns Hopkins University]
|c October 6, 2022, 2022
|
| 300 |
|
|
|a 1 PDF file (17 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Aron, Joshua S.
|e [author]
|
| 700 |
1 |
|
|a Bernstein, David E.
|e [author]
|
| 700 |
1 |
|
|a Flanigan, Colleen
|e [author]
|
| 710 |
2 |
|
|a New York (State)
|b AIDS Institute
|
| 710 |
2 |
|
|a New York (State)
|b AIDS Institute
|
| 710 |
2 |
|
|a Clinical Guidelines Program
|
| 710 |
2 |
|
|a Johns Hopkins University
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 500 |
|
|
|a Caption title. - At head of title: Clinical Guidelines Program. - Description based on online resource; title from PDF caption title (viewed February 21, 2024)
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK598240
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This guideline on pretreatment assessment of patients with chronic hepatitis C virus (HCV) was developed by the New York State Department of Health AIDS Institute (NYSDOH AI) to guide primary care providers and other practitioners in New York State in all aspects of treating and curing patients with chronic HCV. The guideline aims to achieve the following goals: Provide evidence-based treatment guidelines to New York State clinicians to increase the number of New York State residents with chronic HCV who are treated and cured. Provide guidance to clinicians on key pretreatment assessment criteria to ensure that HCV medications are prescribed safely and correctly and that all patients receive the highest quality of care. Provide evidence-based clinical recommendations to support the goals of the New York State Hepatitis C Elimination Plan (NY Cures HepC)
|